Company
When we’re in,
we are all in
Extraordinary moments can happen any day in science.
We work to bring the extraordinary into everyday moments for patients.
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Guided by science and our collective expertise, we work closely with patients to understand real-world challenges and develop meaningful solutions to meet their needs. This collaborative spirit extends across all teams, where diverse perspectives drive innovation.
See how we foster open collaboration and fearless conversations.
We thrive when people come first
We believe that patients benefit when we trust and empower our people to do their best work in the most authentic way.
9
corporate offices worldwide
4
global research sites
1,500+
team members*
*as of June 30, 2025
Count us in
Management team
Our management team has extensive biopharmaceutical experience and a proven track record in research, drug development, and commercialization. The team embodies our culture, setting the tone for an organization that acts boldly and thinks creatively.
Board of directors
Our board of directors brings impressive business and medical credentials to our company. Each board member shares a passion for delivering life-altering therapies to people facing serious diseases.
See some of our proudest moments
From the launch of our first therapy to the clinical studies we’re conducting today, these are some of the most significant achievements in our history that we’re proud to share.
2025
Insmed welcomes Her Royal Highness The Princess Royal to the opening ceremony of its new research lab in Cambridge, UK.
2025
Insmed is certified as a Great Place to Work® in the U.S. for the fifth year in a row. The company is also listed among the UK’s Best Places to Work by The Sunday Times for the second year in a row.
2024
Insmed is ranked No. 1 on Science magazine’s Top Biopharma Employers List for the fourth year in a row and listed as one of BioSpace’s Best Places to Work.
2024
Insmed announces topline results from its Phase 3 ASPEN study.
2023
Insmed announces topline results from its Phase 3 ARISE study.
2022
Insmed holds its inaugural Global Day of Good, a company-wide day of service to support the communities where employees live and work.
2021-2022
Insmed establishes new Research facilities in New Hampshire and San Diego to support the evolution of its fourth pillar.
2021
Insmed’s first product is approved and launches in Japan.
2020
Insmed’s first product is approved in Europe; initial country launches begin.
2019
Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth.
2017
Insmed establishes a subsidiary in Japan.
2016
Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.
2013
Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.
2000
Transave pioneers the early development of an inhaled liposomal antibiotic, an advancement that will later enable the approval of the Company’s first therapy.
1999-2000
Insmed is incorporated in the Commonwealth of Virginia and becomes a public company (INSM) after acquiring Celtrix Pharmaceuticals in a reverse merger.
1997
Transave is founded as a private company by Dr. Frank Pilkiewicz in Monmouth Junction, NJ, to develop inhaled pharmaceuticals for the treatment of lung diseases.
1988
Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, VA, to develop medicines to treat diabetes.
Your Privacy Choices